Trial Profile
Phase 4 Study on Olmesartan, an Angiotensin Receptor Blocker, on Ambulatory Blood Pressure Change, Vitamin D Levels and Urinary Sodium Excretion of Patients With Hypertension.
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 09 Dec 2009 Planned number of patients changed from 200 to 100 as reported by ClinicalTrials.gov.
- 06 Mar 2009 New trial record